Dynamics and specificities of T cells in cancer immunotherapy
G Oliveira, CJ Wu - Nature Reviews Cancer, 2023 - nature.com
Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …
Challenges in liver cancer and possible treatment approaches
Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth.
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
C Puig-Saus, B Sennino, S Peng, CL Wang, Z Pan… - Nature, 2023 - nature.com
Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …
T cell dysfunction in cancer
DS Thommen, TN Schumacher - Cancer cell, 2018 - cell.com
Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …
Integrative clinical genomics of metastatic cancer
Metastasis is the primary cause of cancer-related deaths. Although The Cancer Genome
Atlas has sequenced primary tumour types obtained from surgical resections, much less …
Atlas has sequenced primary tumour types obtained from surgical resections, much less …
Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy
A Durgeau, Y Virk, S Corgnac… - Frontiers in …, 2018 - frontiersin.org
Recent advances in cancer treatment have emerged from new immunotherapies targeting T-
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …
Spatial multi-omics of human skin reveals KRAS and inflammatory responses to spaceflight
Spaceflight can change metabolic, immunological, and biological homeostasis and cause
skin rashes and irritation, yet the molecular basis remains unclear. To investigate the impact …
skin rashes and irritation, yet the molecular basis remains unclear. To investigate the impact …
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
JM Chauvin, O Pagliano, J Fourcade… - The Journal of …, 2015 - Am Soc Clin Investig
T cell Ig and ITIM domain (TIGIT) is an inhibitory receptor expressed by activated T cells,
Tregs, and NK cells. Here, we determined that TIGIT is upregulated on tumor antigen …
Tregs, and NK cells. Here, we determined that TIGIT is upregulated on tumor antigen …
Combined magnetic hyperthermia and immune therapy for primary and metastatic tumor treatments
Cancer immunotherapy shows promising potential in future cancer treatment but
unfortunately is clinically unsatisfactory due to the low therapeutic efficacy and the possible …
unfortunately is clinically unsatisfactory due to the low therapeutic efficacy and the possible …
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
PG Coulie, BJ Van den Eynde… - Nature Reviews …, 2014 - nature.com
In this Timeline, we describe the characteristics of tumour antigens that are recognized by
spontaneous T cell responses in cancer patients and the paths that led to their identification …
spontaneous T cell responses in cancer patients and the paths that led to their identification …